Breaking News Instant updates and real-time market news.

WMT

Walmart

$94.43

0.52 (0.55%)

, X

U.S. Steel

$30.24

-0.24 (-0.79%)

07:35
10/02/18
10/02
07:35
10/02/18
07:35

Unusual call flow in option market yesterday

Notable call activity was cited Monday in Wal-Mart (WMT), US Steel (X), Gilead (GILD), Ctrip.com (CTRP), ArcelorMittal (MT), Neptune Technologies (NEPT), Shire (SHPG), Cree (CREE), and Iridium (IRDM).

WMT

Walmart

$94.43

0.52 (0.55%)

X

U.S. Steel

$30.24

-0.24 (-0.79%)

GILD

Gilead

$77.99

0.77 (1.00%)

CTRP

Ctrip

$37.16

(0.00%)

MT

ArcelorMittal

$31.14

0.28 (0.91%)

NEPT

Neptune Wellness

$4.59

0.72 (18.60%)

SHPG

Shire

$178.12

-3.19 (-1.76%)

CREE

Cree

$37.52

-0.34 (-0.90%)

IRDM

Iridium

$22.65

0.15 (0.67%)

  • 02

    Oct

  • 03

    Oct

  • 22

    Oct

  • 28

    Oct

  • 02

    Nov

  • 15

    Nov

  • 21

    Dec

  • 03

    Mar

WMT Walmart
$94.43

0.52 (0.55%)

09/27/18
MSCO
09/27/18
NO CHANGE
MSCO
Walmart, Kroger to see margin pain from 'war of attrition,' says Morgan Stanley
Morgan Stanley analyst Simeon Gutman said food retail disruption is accelerating as both grocers and consumers head online and he projects that industry EBIT margins, which are "already slim at 3%," could shrink by nearly a third by 2023. He is incrementally more cautious on Kroger (KR) and has "meaningfully" lowered his EBIT and EPS forecasts, stating that while the company and Walmart (WMT) can both take share, "margin pain" is likely in the process of their "war of attrition" in grocery with Amazon (AMZN), each other and a number of additional competitors. Consensus estimates expect stable margins at Kroger and Walmart, which appears challenging to Gutman, he tells investors. The analyst keeps Equal Weight ratings on both traditional retailers and an Overweight rating on Amazon, arguing that it should be able to leverage Prime and its fast-growing high-margin businesses to invest more heavily while still driving higher profitability.
09/25/18
MSCO
09/25/18
NO CHANGE
Target $2500
MSCO
Overweight
Amazon should increase focus on autonomous driving, says Morgan Stanley
Morgan Stanley analyst Brian Nowak makes the case that autonomous driving technology should be where Amazon (AMZN) invests next, stating that Alphabet's (GOOGL) Waymo partnering with Walmart (WMT) and shopping center owner DDR (DDR) to drive shoppers to stores is "just the beginning." He sees the potential for a deeper integration between Google Shopping and Waymo autonomous cars to deliver retailers' in-store or warehouse inventory to consumers, and sees Amazon needing a defense against a stronger potential long-term Waymo retail offering. Nowak also notes that Amazon is already investing in its own delivery network and contends that investing in an autonomous offering is just an extension of this strategy in many ways. Additionally, the analyst sees a small relative upfront investment, the potential for large shipping savings and ways to leverage the value of miles driven. Nowak maintains an Overweight rating and $2,500 price target on Amazon shares.
09/25/18
CLVD
09/25/18
NO CHANGE
CLVD
Neutral
Walmart Q3 comps trending above consens, says at Cleveland Research
Cleveland Research analyst Scott Bender's checks indicate sales trends remain strong for Walmart's Q3-to-date and appear to be trending above consensus expectations with fairly steady trends in grocery despite tough comps. The analyst is modeling Q3 US comp store sales of up 3.5%-4%, versus consensus of up 2.8%.
09/26/18
SBSH
09/26/18
INITIATION
Target $13
SBSH
Neutral
Hostess Brands initiated with a Neutral at Citi
Citi analyst Alexis Borden started Hostess Brands (TWNK) with a Neutral rating and $13 price target. The analyst sees a "host of questions" over Hostess' near-to-medium term outlook due to the recent revenue headwinds from lost Walmart (WMT) display space, heightened cost inflation pressures and continued "sluggish" Sweet Baked Goods category growth. As such, Borden is cautious on the shares near-term.
X U.S. Steel
$30.24

-0.24 (-0.79%)

09/27/18
LBOW
09/27/18
NO CHANGE
Target $49
LBOW
Buy
U.S. Steel estimates lowered on OCTG survey weakness at Longbow
Longbow analyst Chris Olin's latest sruvey of energy metal distributors and traders showed a deceleration in shipment growth reported by OCTG. Olin believes slowing end market demand growth, excess distribution inventories and modestly lower trending spot prices could ultimately limit Tubular Segment upside over the next 2-3 quarters, and when combined with negative momentum in carbon steel, puts $650M EBIT guidance at risk. The analyst lowered U.S. Steel's 2018 earnings forecast to $5.71 from $5.78, but maintains a Buy rating saying the company is positioned for continued earnings growth in 2019 as sheet/tube contracts stabilize at higher levels and US production moves towards 11-12M tons.
08/27/18
08/27/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. MORGAN STANLEY DOUBLE DOWNGRADES U.S. STEEL: Morgan Stanley analyst Piyush Sood double downgraded U.S. Steel (X) to Underweight from Overweight as he notes that steel prices are falling and he believes the recent price peak is "firmly behind" the market. Sood lowered his price target on U.S. Steel shares to $30 from $44. He prefers AK Steel (AKS), which he upgraded to Overweight from Equal Weight citing its good free cash flow prospects, and also prefers Steel Dynamics (STLD), which he also upgraded to Overweight from Equal Weight. PAPA JOHN'S UPGRADED TO BUY: Kalinowski Equity Research's Mark Kalinowski upgraded Papa John's (PZZA) to Buy from Neutral as he believes the reported hiring of Bank of America and Lazard increases the odds of a favorable outcome over the next 12 months, including the possibility of an acquisition. He noted that CNBC reports the company "isn't currently exploring a sale," but he believes a sale makes a lot of sense. BLOOM ENERGY CUT TO UNDERPERFORM: Credit Suisse analyst Michael Weinstein downgraded Bloom Energy (BE) to Underperform from Neutral, with a $24 price target on the stock, on valuation. While the analyst acknowledged the disruptive potential of Bloom Energy's technology, the stock is now trading at a premium. Although the company has shown impressive success so far, much work remains to be done to continue lowering costs and deliver next generation improvements, he contended. WEDBUSH CUTS CHIPOTLE TO UNDERPERFORM: Wedbush analyst Nick Setyan downgraded Chipotle Mexican Grill (CMG) to Underperform from Neutral and lowered his price target for the shares to $445 from $450. Setyan sees increased risk to Chipotle's near-term same-store-sales growth and margin expectations, and continues to see risk to margin expectations through 2020. Quarter-to-date checks suggest risk to the current Q3 consensus same-store-sales growth expectation, Setyan said. Further, the analyst believes that while theoretical drivers towards 2019 same-store-sales growth expectations exist, the risks are underappreciated.
09/04/18
UBSW
09/04/18
NO CHANGE
UBSW
UBS still cautious on steel sector, but says caution already priced into stocks
UBS analyst Andreas Bokkenheuser said he remains cautious on the steel sector and said his research shows there is more imports on flat steel than rolled. That is more negative for US Steel (X) and AK Steel (AKS) than Nucor (NUE) and Steel Dynamics (STLD). He also believes the shares are pricing in a steel price correction already, so he expects the equities to outperform the physical prices.
10/02/18
DBAB
10/02/18
DOWNGRADE
Target $35
DBAB
Hold
U.S. Steel downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Chris Terry downgraded U.S. Steel to Hold and lowered his price target for the shares to $35 from $47. The analyst says he's becoming more cautious on steel stocks.
GILD Gilead
$77.99

0.77 (1.00%)

09/13/18
JPMS
09/13/18
INITIATION
Target $140
JPMS
Overweight
Galapagos NV initiated with an Overweight at JPMorgan
JPMorgan analyst James Quigley started Galapagos NV (GLPG) with an Overweight rating and $140 price target. The company's key value driver is filgotinib, a selective JAK1 inhibitor which has shown potential best in class data in inflammatory diseases and is licensed to Gilead (GILD), Quigley tells investors in a research note. The analyst forecasts peak in market filgotinib sales of EUR 4.4B. Quigley also sees value in Galapagos' wholly owned GLPG1690, which he says could be the first drug to halt disease progression in idiopathic pulmonary fibrosis.
09/25/18
JPMS
09/25/18
NO CHANGE
JPMS
Overweight
Diplomat Pharmacy weakness on Gilead generics overdone, says JPMorgan
JPMorgan analyst Lisa Gill says the weakness yesterday in shares of Diplomat Pharmacy (DPLO) following Gilead's (GILD) announcement that it will be launching new authorized generic versions of hepatitis C treatments Epclusa and Harvoni is a "significant overreaction." Hepatitis C represents a relatively small portion of revenue for Diplomat Pharmacy, and as such, these two drugs are not material, Gill tells investors in a research note. Further, the analyst believes it is unclear whether payors will adopt the authorized generic in lieu of continuing to receive rebates on the branded drugs. In addition, Gill thinks Diplomat should be able to purchase the new authorized generics at a discount to the new list price with a higher gross margin spread relative to the brand. The analyst keeps an Overweight rating on the shares.
09/25/18
JEFF
09/25/18
INITIATION
Target $75.5
JEFF
Buy
Cambrex initiated with a Buy at Jefferies
Jefferies analyst David Windley started Cambrex (CBM) with a Buy rating and $75.50 price target. The analyst sees the company, as a leading manufacturer of small molecule active pharmaceutical ingredients, benefiting from increased API outsourcing. He adds that his Gilead (GILD) analysis, Cambrex's top customer, is "differentiated and positive."
10/01/18
CANT
10/01/18
INITIATION
Target $87
CANT
Overweight
Gilead initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young started Gilead Sciences with an Overweight rating and $87 price target.
CTRP Ctrip
$37.16

(0.00%)

05/21/18
THCP
05/21/18
UPGRADE
Target $50
THCP
Buy
Ctrip upgraded to Buy from Hold at TH Data Capital
TH Data Capital analyst Tian Hou upgraded Ctrip to Buy with a $50 price target. The analyst expects a traffic recovery to drive better Q1 results when Ctrip reports tomorrow. The company's business has "already stabilized and is on its way to recovery," Hou tells investors in a pre-earnings research note. He sees Q1 as the likely the bottom for Ctrip, and expects its results to recover in the rest of 2018.
07/13/18
GUGG
07/13/18
NO CHANGE
GUGG
Ctrip estiamtes reduced below conesnsus at Guggenheim
Guggenheim analyst Jake Fuller lowered Ctrip revenue estimates below consensus given ongoing headwinds from the recent service-oriented product changes and slowdown in May and June traffic trends from the strong April.
06/26/18
DAIW
06/26/18
UPGRADE
DAIW
Buy
Ctrip upgraded to Buy from Outperform at Daiwa
05/21/18
05/21/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Snap (SNAP) upgraded to Neutral from Sell at MoffettNathanson. 2. ProsHoldings (PROS) upgraded to Outperform from Market Perform at Northland with analyst Tim Klasell citing last week's annual user conference and analyst meetings. 3. Ctrip (CTRP) upgraded to Buy from Hold at TH Data Capital with analyst Tian Hou saying the company's business has "already stabilized and is on its way to recovery." 4. Sempra Energy (SRE) upgraded to Buy from Hold at Argus with analyst Jacob Kilstein citing anticipated earnings accretion from the recent purchase of a majority stake in Oncor, favorable regulations, and the growing base rate at its California utilities. 5. Dillard's (DDS) upgraded to Buy from Underperform at BofA/Merrill with analyst Heather Balsky saying she expects improved consumer sentiment, especially in the energy market, to support positive comps and drive multiple expansion. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MT ArcelorMittal
$31.14

0.28 (0.91%)

02/20/18
BOFA
02/20/18
UPGRADE
BOFA
Buy
ArcelorMittal upgraded to Buy from Neutral at BofA/Merrill
03/09/18
COWN
03/09/18
NO CHANGE
COWN
Cowen sees upside for entire steel group with tariff decision
Cowen analyst Novid Rassouli said he sees upside for the entire steel group following the announced decision on tariffs for imported steel and aluminum. He said the entire steel group is trading at a discount to current spot steel prices. The analyst also believes Century Aluminum (CENX) will be the biggest beneficiary on the aluminum side, as he sees it as the best vehicle to capitalize. Publicly traded companies in the steel space include U.S. Steel (X), Steel Dynamics (STLD), AK Steel (AKS), Cleveland-Cliffs (CLF), Nucor (NUE) and ArcelorMittal (MT).
04/30/18
JPMS
04/30/18
DOWNGRADE
JPMS
Neutral
Outokumpu downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Luke Nelson downgraded Outokumpu (OUTKY) to Neutral and lowered his price target for the shares to EUR 6 from EUR 11.60. ArcelorMittal (MT) remains the analyst's top pick in European Steel.
06/07/18
UBSW
06/07/18
DOWNGRADE
UBSW
Sell
ArcelorMittal downgraded to Sell from Buy at UBS
NEPT Neptune Wellness
$4.59

0.72 (18.60%)

SHPG Shire
$178.12

-3.19 (-1.76%)

09/07/18
BREN
09/07/18
DOWNGRADE
BREN
Hold
Shire downgraded to Hold from Buy at Berenberg
Berenberg analyst Klara Fernandes downgraded Shire (SHPG) to Hold saying the current valuation offers limited potential upside ahead of the pending takeover by Takeda Pharmaceutical (TKPYY).
09/04/18
09/04/18
DOWNGRADE

Market Perform
Shire downgraded to Market Perform as spread narrows at Bernstein
As previously reported, Bernstein analyst Aaron Gal downgraded Shire (SHPG) to Market Perform from Outperform. The analyst notes that he current controversy on Shire is the risk/reward into the closing of the Takeda (TKPYY) acquisition, and over the past few weeks deal spread narrowed, and the fundamentals have gotten a bit tougher in ADHD, HAE and Hemophilia.
09/04/18
BERN
09/04/18
DOWNGRADE
BERN
Market Perform
Shire downgraded to Market Perform from Outperform at Bernstein
05/09/18
LEER
05/09/18
NO CHANGE
LEER
Takeda/Shire transaction shows path for consolidation, says Leerink
Leerink analyst Geoffrey Porges notes that Takeda (TKPYY) confirmed its intention and agreement to purchase Shire (SHPG) for $62B in cash and stock. For the broader biopharma industry, the analyst believes Takeda's ability to lever up to an estimated 5.4x net debt/EBITDA suggests that investors are underestimating the ability of large cap biopharma companies to pursue large transactions. Nearly all of the large cap biopharma companies face looming growth issues or suffer under revenue-concentration risk discounts that could be mitigated by large-scale acquisitions, he contends. Porges believes that if Takeda can execute the Shire acquisition while checking the boxes of investor demands of a net positive ROIC, instant EPS accretion, maintaining an investment grade credit rating, and massive synergy savings, then others in the biopharma industry with stronger balance sheets and larger valuations can contemplate transactions that are substantially larger even than Shire.
CREE Cree
$37.52

-0.34 (-0.90%)

09/11/18
ROTH
09/11/18
UPGRADE
ROTH
Buy
Cree upgraded to Buy from Neutral at Roth Capital
08/28/18
08/28/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. II-VI (IIVI) initiated with a Buy at Deutsche Bank while Cree (CREE) was initiated with a Hold. 2. Arlo Technologies (ARLO) initiated with an Outperform at Imperial Capital and Cowen, a Buy at Deutsche Bank, a Neutral at BofA/Merrill and Guggenheim, as well as a Market Perform at Raymond James. 3. AnaptysBio (ANAB) initiated with an Overweight at Cantor Fitzgerald. 4. Oshkosh (OSK) initiated with a Neutral at Buckingham. 5. nLight (LASR) initiated with a Sell at Benchmark. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/28/18
DBAB
08/28/18
INITIATION
Target $47
DBAB
Hold
Deutsche views Cree as fairly valued, initiates with Hold rating
Deutsche Bank analyst Sidney Ho last night initiated coverage of Cree with a Hold rating and $47 price target. The company's This transformation to focus on the fast-growing silicon carbide market has not gone unnoticed, with the stock nearly doubling since a year ago, Ho tells investors in a research note. The analyst believes Cree's current valuation seems to reflect most of its earnings growth potential. As such, he finds the stock fairly valued.
09/11/18
09/11/18
UPGRADE
Target $60

Buy
Cree upgraded to Buy on robust demand at Roth Capital
As previously reported, Roth Capital analyst Craig Irwin upgraded Cree to Buy from Neutral and raised his price target on the shares to $60 from $50 after attending the ECSCRM conference in Birmingham, U.K. The analyst notes that SiC chips OEMs talked quietly about approximately 50 new MOSFET programs that start ramping in 2019, where he expects Cree to retain strong share. While wafer pricing will see a long-term downward trajectory to facilitate growth, the analyst does not expect any sharp price drops, so technology and process changes should allow Wolfspeed's wafer business to preserve impressive gross margins.
IRDM Iridium
$22.65

0.15 (0.67%)

05/09/18
BWSF
05/09/18
INITIATION
Target $22
BWSF
Buy
Iridium initiated with a Buy at BWS Financial
BWS Financial analyst Hamed Khorsand started Iridium Communications with a Buy rating and $22 price target. The analyst views the satellite launch scheduled for May 19 as the "next immediate catalyst for the stock."
05/09/18
05/09/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Cleveland-Cliffs (CLF) initiated with a Buy at Seaport Global. 2. Amneal Pharmaceuticals (AMRX) initiated with a Buy at Deutsche Bank. 3. Iridium (IRDM) initiated with a Buy at BWS Financial. 4. ServiceMaster (SERV) initiated with a Buy at Buckingham while Rollins (ROL) was initiated with a Neutral at Buckingham. 5. Eiger BioPharmaceuticals (EIGR) initiated with a Buy at B. Riley FBR. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/27/18
SIDC
08/27/18
DOWNGRADE
SIDC
Neutral
Iridium downgraded to Neutral from Buy at Sidoti
09/10/18
NORL
09/10/18
DOWNGRADE
Target $14
NORL
Underperform
Iridium downgraded to Underperform from Market Perform at Northland
Northland analyst Paul Penney downgraded Iridium to Underperform from Market Perform as he believes the stock's current price does not adequately account for a number of mounting risks, such as targets for its Certurs Broadband segment that he sees as ambitious and the uncertainty of the renewal of its contract with the Department of Defense. Penney lowered his price target on Iridium shares to $14 from $14.75.

TODAY'S FREE FLY STORIES

BIIB

Biogen

$319.85

-10.4 (-3.15%)

14:57
10/20/18
10/20
14:57
10/20/18
14:57
Conference/Events
Biogen to host conference call »

Chief Medical Officer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 25

    Oct

SELB

Selecta Biosciences

$13.80

-1.34 (-8.85%)

14:13
10/20/18
10/20
14:13
10/20/18
14:13
Conference/Events
Selecta Biosciences to host conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

TROV

Trovagene

$1.12

-0.03 (-2.61%)

14:11
10/20/18
10/20
14:11
10/20/18
14:11
Conference/Events
Trovagene to host conference call »

Management provides an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLS

Sellas Life Sciences

$1.56

-0.24 (-13.33%)

13:54
10/20/18
10/20
13:54
10/20/18
13:54
Conference/Events
Sellas Life Sciences to host conference call »

Management provides a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 07

    Nov

NVS

Novartis

$87.19

0.95 (1.10%)

13:50
10/20/18
10/20
13:50
10/20/18
13:50
Conference/Events
Novartis to host conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 07

    Nov

UA

Under Armour

$16.79

-0.365 (-2.13%)

, UAA

Under Armour

$18.20

-0.42 (-2.26%)

12:43
10/20/18
10/20
12:43
10/20/18
12:43
Periodicals
Under Armour stock could triple, Barron's says »

Under Armour has had a…

UA

Under Armour

$16.79

-0.365 (-2.13%)

UAA

Under Armour

$18.20

-0.42 (-2.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 30

    Oct

  • 27

    Nov

  • 03

    Mar

STZ

Constellation Brands

$222.98

-2.36 (-1.05%)

, CGC

Canopy Growth

$46.87

-1.99 (-4.07%)

12:37
10/20/18
10/20
12:37
10/20/18
12:37
Periodicals
Constellation Brands changing CEOs, not marijuana strategy, Barron's says »

Constellation Brands…

STZ

Constellation Brands

$222.98

-2.36 (-1.05%)

CGC

Canopy Growth

$46.87

-1.99 (-4.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 14

    Nov

CFG

Citizens Financial

$36.36

1.44 (4.12%)

, AAPL

Apple

$219.28

3.3 (1.53%)

12:33
10/20/18
10/20
12:33
10/20/18
12:33
Periodicals
Citizens Financial stock worth buying, Barron's says »

Citizens Financial (CFG)…

CFG

Citizens Financial

$36.36

1.44 (4.12%)

AAPL

Apple

$219.28

3.3 (1.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$153.95

-1 (-0.65%)

, AAPL

Apple

$219.28

3.3 (1.53%)

12:26
10/20/18
10/20
12:26
10/20/18
12:26
Periodicals
Netflix emerged as winner in new way to rank big tech stocks risk, Barron's says »

A year ago,…

FB

Facebook

$153.95

-1 (-0.65%)

AAPL

Apple

$219.28

3.3 (1.53%)

AMZN

Amazon.com

$1,763.91

-7.54 (-0.43%)

NFLX

Netflix

$332.69

-14.02 (-4.04%)

GOOG

Alphabet

$1,096.41

8.51 (0.78%)

GOOGL

Alphabet Class A

$1,104.66

7.43 (0.68%)

DIS

Disney

$118.81

2.55 (2.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 30

    Oct

  • 07

    Nov

  • 08

    Nov

  • 13

    Nov

  • 03

    Mar

BABA

Alibaba

$142.90

1.1 (0.78%)

, TCEHY

Tencent

$0.00

(0.00%)

12:17
10/20/18
10/20
12:17
10/20/18
12:17
Periodicals
Chinese internet giants down, not out, Barron's says »

Alibaba (BABA), Tencent…

BABA

Alibaba

$142.90

1.1 (0.78%)

TCEHY

Tencent

$0.00

(0.00%)

BIDU

Baidu

$191.93

0.1 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 02

    Nov

BLK

BlackRock

$401.61

1.74 (0.44%)

, IVZ

Invesco

$22.00

0.74 (3.48%)

12:13
10/20/18
10/20
12:13
10/20/18
12:13
Periodicals
Fund companies sued by own employees over pricey 401k plans, Barron's says »

BlackRock (BLK),…

BLK

BlackRock

$401.61

1.74 (0.44%)

IVZ

Invesco

$22.00

0.74 (3.48%)

TROW

T. Rowe Price

$100.13

0.31 (0.31%)

SCHW

Charles Schwab

$46.81

0.11 (0.24%)

MTB

M&T Bank

$162.72

2.09 (1.30%)

MS

Morgan Stanley

$46.43

0.4 (0.87%)

JPM

JPMorgan

$107.92

-0.21 (-0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 24

    Oct

  • 26

    Feb

JPM

JPMorgan

$107.92

-0.21 (-0.19%)

, BLK

BlackRock

$401.61

1.74 (0.44%)

12:04
10/20/18
10/20
12:04
10/20/18
12:04
Periodicals
Khashoggi case puts financial ties to Saudis under strain, Barron's says »

The suspected killing of…

JPM

JPMorgan

$107.92

-0.21 (-0.19%)

BLK

BlackRock

$401.61

1.74 (0.44%)

BX

Blackstone

$34.66

-0.61 (-1.73%)

AMC

AMC Entertainment

$19.81

0.18 (0.92%)

IMAX

Imax

$22.45

-0.11 (-0.49%)

SIX

Six Flags

$66.40

-1.16 (-1.72%)

WWE

WWE

$82.02

-1.49 (-1.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 13

    Nov

  • 14

    Nov

  • 26

    Feb

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, ALXN

Alexion

$125.96

-0.63 (-0.50%)

04:55
10/20/18
10/20
04:55
10/20/18
04:55
Conference/Events
The ACR and ARHP to hold annual meeting »

American College of…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

ALXN

Alexion

$125.96

-0.63 (-0.50%)

AMGN

Amgen

$201.75

-1.03 (-0.51%)

AUPH

Aurinia Pharmaceuticals

$5.56

-0.13 (-2.28%)

BMY

Bristol-Myers

$54.31

-1.7 (-3.04%)

CELG

Celgene

$82.42

-0.52 (-0.63%)

DGX

Quest Diagnostics

$102.49

0.12 (0.12%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FLXN

Flexion

$18.96

0.33 (1.77%)

GILD

Gilead

$73.27

-0.9 (-1.21%)

GSK

GlaxoSmithKline

$40.87

1.25 (3.16%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

RARE

Ultragenyx

$63.33

-0.77 (-1.20%)

QDEL

Quidel

$64.68

-2.85 (-4.22%)

PFE

Pfizer

$44.50

0.48 (1.09%)

NVS

Novartis

$87.19

0.95 (1.10%)

MRK

Merck

$72.34

0.12 (0.17%)

MCK

McKesson

$132.36

-0.34 (-0.26%)

LLY

Eli Lilly

$111.91

-1.4 (-1.24%)

TMO

Thermo Fisher

$227.13

-2.51 (-1.09%)

TKPYY

Takeda Pharmaceutical

$0.00

(0.00%)

SELB

Selecta Biosciences

$13.80

-1.34 (-8.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 02

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 09

    Nov

  • 27

    Nov

  • 11

    Jan

  • 16

    Feb

  • 18

    Feb

  • 28

    Apr

  • 13

    May

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, DCPH

Deciphera

$22.22

-4.97 (-18.28%)

04:55
10/20/18
10/20
04:55
10/20/18
04:55
Conference/Events
European Society for Medical Oncology (ESMO) to hold a conference »

ESMO 2018 Congress to be…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

DCPH

Deciphera

$22.22

-4.97 (-18.28%)

TSRO

Tesaro

$41.81

-1.19 (-2.77%)

IMGN

ImmunoGen

$7.44

-0.355 (-4.56%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

CRSP

Crispr Therapeutics

$36.02

-1.18 (-3.17%)

CLVS

Clovis

$26.41

-3.54 (-11.82%)

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

RHHBY

Roche

$0.00

(0.00%)

NCNA

NuCana

$18.90

1.9 (11.18%)

CRVS

Corvus Pharmaceuticals

$8.01

-0.1 (-1.23%)

NTGN

Neon Therapeutics

$8.88

0.56 (6.73%)

NKTR

Nektar

$48.23

-1.33 (-2.68%)

EXEL

Exelixis

$16.27

-0.25 (-1.51%)

AVEO

Aveo Pharmaceuticals

$2.50

-0.03 (-1.19%)

KURA

Kura Oncology

$14.38

-1.18 (-7.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 22

    Oct

  • 24

    Oct

  • 28

    Oct

  • 30

    Oct

  • 01

    Nov

  • 01

    Nov

  • 02

    Nov

  • 02

    Nov

  • 06

    Nov

  • 07

    Nov

  • 10

    Nov

  • 26

    Nov

  • 27

    Nov

  • 24

    Dec

  • 14

    Jan

  • 28

    Apr

  • 13

    May

A

Agilent

$64.47

-1.28 (-1.95%)

, AGLE

Aeglea BioTherapeutics

$9.32

-0.58 (-5.86%)

04:55
10/20/18
10/20
04:55
10/20/18
04:55
Conference/Events
American Society of Human Genetics to hold a conference »

ASHG Conference 2018 will…

A

Agilent

$64.47

-1.28 (-1.95%)

AGLE

Aeglea BioTherapeutics

$9.32

-0.58 (-5.86%)

ALXN

Alexion

$125.96

-0.63 (-0.50%)

RHHBY

Roche

$0.00

(0.00%)

BMRN

BioMarin

$103.31

-0.52 (-0.50%)

BIO

Bio-Rad

$280.96

-3.23 (-1.14%)

MSFT

Microsoft

$108.55

0.01 (0.01%)

ILMN

Illumina

$313.31

-7.98 (-2.48%)

FLDM

Fluidigm

$7.49

-0.45 (-5.67%)

HZNP

Horizon Pharma

$19.07

-0.01 (-0.05%)

NVTA

Invitae

$12.86

-0.23 (-1.76%)

NSTG

NanoString

$15.18

-0.41 (-2.63%)

QGEN

Qiagen

$35.91

0.455 (1.28%)

DGX

Quest Diagnostics

$102.49

0.12 (0.12%)

RTRX

Retrophin

$25.34

0.24 (0.96%)

TMO

Thermo Fisher

$227.13

-2.51 (-1.09%)

WTKWY

Wolters Kluwer

$0.00

(0.00%)

ARQL

ArQule

$4.33

-0.38 (-8.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 21

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 30

    Oct

  • 31

    Oct

  • 01

    Nov

  • 01

    Nov

  • 01

    Nov

  • 07

    Nov

  • 07

    Nov

  • 08

    Nov

  • 13

    Nov

  • 27

    Nov

  • 28

    Nov

  • 24

    Dec

  • 18

    Feb

  • 03

    Mar

CLBR

Caliburn International

$0.00

(0.00%)

18:27
10/19/18
10/19
18:27
10/19/18
18:27
Syndicate
Caliburn International files registration statement for proposed IPO »

Caliburn International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

18:10
10/19/18
10/19
18:10
10/19/18
18:10
General news
Saudi Arabia says Kashoggi killed after fight broke out in consulate, CNBC says 

Reference Link

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$99.62

2.61 (2.69%)

18:02
10/19/18
10/19
18:02
10/19/18
18:02
Hot Stocks
Celanese raises prices on MIBK, MIBC by EUR120/MT in Europe »

Celanese announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

REGN

Regeneron

$389.94

-5.45 (-1.38%)

, SNY

Sanofi

$44.57

0.12 (0.27%)

17:57
10/19/18
10/19
17:57
10/19/18
17:57
Hot Stocks
Regeneron, Sanofi: FDA approves asthma indication for Dupixent »

Regeneron Pharmaceuticals…

REGN

Regeneron

$389.94

-5.45 (-1.38%)

SNY

Sanofi

$44.57

0.12 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 20

    Oct

  • 23

    Oct

  • 28

    Oct

  • 29

    Oct

  • 06

    Nov

  • 28

    Jan

  • 22

    Mar

  • 28

    Apr

  • 13

    May

XLE

Energy Select Sector SPDR

$71.50

-0.67 (-0.93%)

, XLU

Utilities SPDR

$54.57

0.82 (1.53%)

17:55
10/19/18
10/19
17:55
10/19/18
17:55
General news
Week ending ETF Scorecard: Staples, Real Estate, Utilities lead rebound »

S&P500 SECTORS: …

XLE

Energy Select Sector SPDR

$71.50

-0.67 (-0.93%)

XLU

Utilities SPDR

$54.57

0.82 (1.53%)

IYR

DJ US Real Estate Index Fund

$77.83

0.63 (0.82%)

XLP

Consumer Staples Sector SPDR

$54.72

1.225 (2.29%)

XLY

Consumer Discretionary Sector SPDR

$106.34

-1.06 (-0.99%)

XLB

S&P Select Materials SPDR

$53.13

-0.36 (-0.67%)

XLF

Financial Select Sector

$26.66

0.08 (0.30%)

XLV

Health Care Select Sector SPDR

$91.48

-0.93 (-1.01%)

XLK

Technology Select Sector SPDR

$70.00

-0.04 (-0.06%)

XLI

Industrial Select Sector SPDR

$73.17

-0.31 (-0.42%)

GLD

SPDR Gold Trust

$116.01

0.11 (0.09%)

SLV

iShares Silver Trust

$13.74

0.05 (0.37%)

USO

United States Oil Fund

$14.72

0.155 (1.06%)

UNG

United States Natural Gas Fund

$26.81

0.19 (0.71%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$84.90

0.04 (0.05%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$112.69

-0.15 (-0.13%)

TLT

iShares 20+ Year Treasury Bond Fund

$113.73

-0.24 (-0.21%)

IEF

iShares 7-10 Year Treasury Bond ETF

$100.12

-0.12 (-0.12%)

SHY

iShares 1-3 Year Treasury Bond

$82.95

-0.035 (-0.04%)

IWD

iShares Russell 1000 Value

$122.17

0.08 (0.07%)

IWF

iShares Russell 1000 Growth

$145.19

-0.5 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INSW

International Seaways

$21.51

0.41 (1.94%)

17:53
10/19/18
10/19
17:53
10/19/18
17:53
Syndicate
Breaking Syndicate news story on International Seaways »

International Seaways…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNR

Monmouth Real Estate

$15.49

0.08 (0.52%)

17:48
10/19/18
10/19
17:48
10/19/18
17:48
Hot Stocks
Monmouth Real Estate acquires industrial building in New Jersey for $85.25M »

Monmouth Real Estate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

TEUM

Pareteum

$2.47

-0.07 (-2.76%)

17:38
10/19/18
10/19
17:38
10/19/18
17:38
Syndicate
Breaking Syndicate news story on Pareteum »

Pareteum files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 15

    Nov

TEUM

Pareteum

$2.47

-0.07 (-2.76%)

17:36
10/19/18
10/19
17:36
10/19/18
17:36
Syndicate
Breaking Syndicate news story on Pareteum »

Pareteum files $150M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 15

    Nov

NOC

Northrop Grumman

$307.77

-0.445 (-0.14%)

, LMT

Lockheed Martin

$328.22

0.21 (0.06%)

17:33
10/19/18
10/19
17:33
10/19/18
17:33
Periodicals
Trump to meet CEOs of Boeing, Lockheed Martin, General Dynamics, Reuters reports »

President Donald Trump…

NOC

Northrop Grumman

$307.77

-0.445 (-0.14%)

LMT

Lockheed Martin

$328.22

0.21 (0.06%)

BA

Boeing

$356.28

-3 (-0.84%)

GD

General Dynamics

$190.43

-0.76 (-0.40%)

BAESY

BAE Systems

$0.00

(0.00%)

HON

Honeywell

$153.49

-1.73 (-1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 30

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.